| |
HFrEF, n = 73
|
HFpEF, n = 45
|
P value
|
|---|
|
Thazides
|
5 (6.85%)
|
3 (6.7%)
|
0.969
|
|
Loop diuretics
|
40 (54.8%)
|
28 (62.22%)
|
0.428
|
|
Nitrates
|
39 (53.4%)
|
28 (62.22%)
|
0.349
|
|
Warfarin
|
17 (23.3%)
|
14 (31.11%)
|
0.348
|
|
Clopidogril
|
41 (56.2%)
|
17 (37.8%)
|
0.052
|
|
CCB
|
2 (2.74%)
|
6 (13.33%)
|
0.026
|
|
Amiodarone
|
10 (13.7%)
|
7 (15.6%)
|
0.780
|
|
Unfractunated heparin
|
19 (26.02%)
|
15 (33.33%)
|
0.395
|
|
LMWH
|
52 (71.23%)
|
27 (60%)
|
0.208
|
|
Lytic therapy
|
24 (32.88%)
|
8 (17.8%)
|
0.073
|
|
Aldosterone antagonist
|
32 (43.8%)
|
18 (40%)
|
0.682
|
|
Digixon
|
19 (26.03%)
|
13 (28.9%)
|
0.734
|
|
PPIH blockers
|
55 (75.34%)
|
42 (93.3%)
|
0.013
|
|
Warfarin A
|
10 (13.7%)
|
12 (26.7%)
|
0.079
|
|
ASA
|
60 (82.2%)
|
28 (62.22%)
|
0.016
|
|
Beta-blockers
|
27 (37%)
|
18 (40%)
|
0.743
|
|
ACEI
|
38 (52.1%)
|
22 (49%)
|
0.738
|
|
ARBs
|
8 (11%)
|
10 (22.22%)
|
0.098
|
|
Statin
|
58 (79.5%)
|
32 (71.1%)
|
0.301
|
- CCB calcium channel blockers, LMWH low molecular weight heparin, ASA acetyl salsylic acid, ACEI angiotensin converting enzyme inhibitor, ARBS angiotensin receptor blockers
